Dini G, Arcese W, Barbanti M, Biffoni F, Bosi A, Lanino E, Majolino I, Menichella G, Reali G
GITMO (Gruppo Italiano per il Trapianto di Midollo Osseo) Committee.
Bone Marrow Transplant. 1998 Dec;22 Suppl 5:S41-5.
Peripheral blood stem cells (PBSCs) collected following stimulation with cytokines are commonly used for autologous haematopoietic transplants. Currently, PBSCs are being used for syngeneic or allogeneic transplants from matched or haploidentical donors. However, many issues are still unanswered regarding the early or late side-effects cytokines have on recipients and on healthy donors. The aims of this paper were to evaluate the experience acquired worldwide in this field, to define the acceptability of stem cell donation by G-CSF-stimulated apheresis from unrelated donors after the failure of a first donation, and to assess side-effects of G-CSF on unrelated donors. The use of PBSCs has increased tremendously over the last few years and in the near future PBSCs will probably become the most relevant source of stem cells. Studies conducted so far have definitely concluded that G-CSF is safe and well tolerated. Results observed in transplants utilizing marrow stem cells compared with results obtained in transplants utilizing PBSCs have shown that patients undergoing this latter procedure recover earlier, require a lower number of transfusions and spend fewer days in hospital with a consequent decrease in costs. We concluded that a second transplant by G-CSF-stimulated apheresis from an unrelated donor is definitely acceptable and we designed a prospective study to better define all controversial aspects. Donors will be given 10 microg/kg/day of G-CSF subcutaneously for 5 days. One or two PBSC collection procedures will be performed: the first on day 5 and the second, if necessary, on day 6. Donors will be surveyed and blood counts monitored in a standardized manner during the process.
细胞因子刺激后采集的外周血干细胞(PBSCs)通常用于自体造血移植。目前,PBSCs正被用于来自匹配或单倍体相合供体的同基因或异基因移植。然而,关于细胞因子对受者和健康供体的早期或晚期副作用,仍有许多问题未得到解答。本文的目的是评估全球在该领域获得的经验,确定首次捐献失败后通过粒细胞集落刺激因子(G-CSF)刺激的单采从无关供体采集干细胞的可接受性,并评估G-CSF对无关供体的副作用。在过去几年中,PBSCs的使用量大幅增加,在不久的将来,PBSCs可能会成为最重要的干细胞来源。迄今为止进行的研究明确得出结论,G-CSF是安全的且耐受性良好。与使用骨髓干细胞的移植结果相比,使用PBSCs的移植结果表明,接受后一种手术的患者恢复得更早,需要的输血次数更少,住院天数更少,从而降低了成本。我们得出结论,由无关供体通过G-CSF刺激的单采进行第二次移植绝对是可以接受的,并且我们设计了一项前瞻性研究以更好地界定所有有争议的方面。供体将皮下注射10微克/千克/天的G-CSF,持续5天。将进行一到两次PBSC采集程序:第一次在第5天进行,如有必要,第二次在第6天进行。在此过程中,将以标准化方式对供体进行调查并监测血细胞计数。